IMRX
NASDAQ
US
Immuneering Corporation - Class A Common Stock
$5.45
▲ +$0.12
(+2.25%)
Vol 597K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$424.9M
ROE
-73.5%
Margin
-9610.0%
D/E
0.00
Beta
0.34
52W
$1–$10
Wall Street Consensus
12 analysts · Apr 20264
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
91.7%
Buy Rating
Price Chart
Similar Stocks
AKBA
Akebia Therapeutics Inc
$427.2M
MNPR
Monopar Therapeutics Inc
$436.4M
CADL
Candel Therapeutics Inc
$310.2M
IVVD
Invivyd Inc
$684.5M
PBYI
Puma Biotechnology Inc
P/E 8.1
$299.8M
DMAC
DiaMedica Therapeutics Inc
$414.5M
CABA
Cabaletta Bio Inc
$210.8M
XOMA
Xoma Royalty Corp
P/E 15.2
$329.3M
IRD
Opus Genetics Inc
$138.6M
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.32 | $-0.18 | +$0.14 |
| Sep 2025 | $-0.40 | $-0.38 | +$0.02 |
| Jun 2025 | $-0.42 | $-0.40 | +$0.02 |
| Mar 2025 | $-0.54 | $-0.42 | +$0.12 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -146.3% | -119.2% | -119.2% | -119.2% | -146.3% | -73.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -9610.0% | -9610.0% | -9610.0% | -9610.0% | -9610.0% |
| Gross Margin | — | 28.0% | 28.0% | 28.0% | 28.0% | 28.0% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.70 | 3.70 | 3.70 | 3.70 | 3.70 | 24.00 |
Key Ratios
ROA (TTM)
-65.0%
P/S (TTM)
849.74
P/B
1.7
EPS (TTM)
$-1.78
CF/Share
$-1.85
52W High
$10.08
52W Low
$1.10
$1.10
52-Week Range
$10.08
How does IMRX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IMRX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
849.7
▲
6513%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.7
▼
33%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IMRX profitability vs Biotechnology peers
ROE
-73.5%
▼
9%
below
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-9610.0%
▼
3251%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
28.0%
▼
64%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-65.0%
▼
39%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
IMRX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
24.0
▲
441%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.3
▼
65%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
IMRX fundamentals radar
IMRX
Peer median
Industry
IMRX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
IMRX vs peers: key metrics
Latest News
No related news yet